Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update
Clicks: 365
ID: 272813
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
79.9
/100
365 views
224 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #3 of 4 articles by views in expert review of clinical immunology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Introduction: JAK, which constitutively binds to some cytokine receptors, plays an important role in cytokine signaling. While JAK is comprised of JAK1, JAK2, JAK3, and Tyk2, more than 40 types of cytokines transmit signals through JAK. Baricitinib is reported to be highly effective in the tr …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (45 words).
Try re-searching for a better abstract.
| Reference Key |
s2019expertbaricitinib
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kubo S;Nakayamada S;Tanaka Y;; |
| Journal | expert review of clinical immunology |
| Year | 2019 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
Lupus Erythematosus
Systemic / immunology
arthritis
rheumatoid / drug therapy*
signal transduction / drug effects*
yoshiya tanaka
rheumatoid / immunology
clinical trials
phase iii as topic
cytokines / immunology
azetidines / therapeutic use*
sulfonamides / therapeutic use*
systemic / drug therapy*
pmid:30987474
doi:10.1080/1744666x.2019.1608821
satoshi kubo
shingo nakayamada
rheumatoid / pathology
janus kinases / immunology
systemic / pathology
signal transduction / immunology
tyk2 kinase / immunology
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.